173 related articles for article (PubMed ID: 30563687)
1. Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.
Marion O; Lhomme S; Del Bello A; Abravanel F; Esposito L; Hébral AL; Lavayssière L; Cointault O; Ribes D; Izopet J; Kamar N
J Hepatol; 2019 Jan; 70(1):206-209. PubMed ID: 30563687
[No Abstract] [Full Text] [Related]
2. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse.
Abravanel F; Lhomme S; Rostaing L; Kamar N; Izopet J
Clin Infect Dis; 2015 Jan; 60(1):96-9. PubMed ID: 25249523
[TBL] [Abstract][Full Text] [Related]
3. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.
Lhomme S; DebRoy S; Kamar N; Abravanel F; Metsu D; Marion O; Dimeglio C; Cotler SJ; Izopet J; Dahari H
Viruses; 2019 Jul; 11(7):. PubMed ID: 31323954
[TBL] [Abstract][Full Text] [Related]
4. Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection.
Marion O; Abravanel F; Izopet J; Kamar N
Transpl Infect Dis; 2019 Apr; 21(2):e13050. PubMed ID: 30663838
[No Abstract] [Full Text] [Related]
5. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
6. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.
Lhomme S; Kamar N; Nicot F; Ducos J; Bismuth M; Garrigue V; Petitjean-Lecherbonnier J; Ollivier I; Alessandri-Gradt E; Goria O; Barth H; Perrin P; Saune K; Dubois M; Carcenac R; Lefebvre C; Jeanne N; Abravanel F; Izopet J
Antimicrob Agents Chemother; 2015 Dec; 60(3):1608-14. PubMed ID: 26711757
[TBL] [Abstract][Full Text] [Related]
7. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.
Debing Y; Gisa A; Dallmeier K; Pischke S; Bremer B; Manns M; Wedemeyer H; Suneetha PV; Neyts J
Gastroenterology; 2014 Nov; 147(5):1008-11.e7; quiz e15-6. PubMed ID: 25181691
[TBL] [Abstract][Full Text] [Related]
8. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient.
Wang Y; Chen G; Pan Q; Zhao J
Gastroenterology; 2018 Mar; 154(4):1199-1201. PubMed ID: 29432746
[No Abstract] [Full Text] [Related]
9. Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM; Gevers TJ; Drenth JP
J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
[TBL] [Abstract][Full Text] [Related]
10. Domestically acquired hepatitis E successfully treated with ribavirin in an Australian liver transplant recipient.
Speers DJ; Ma MX; Faddy HM; Nash M; Bowden S; de Boer B; MacNicholas R; MacQuillan G; Adams L
Med J Aust; 2015 Mar; 202(4):209-11. PubMed ID: 25716605
[No Abstract] [Full Text] [Related]
11. Long-term hepatitis E viral load kinetics in an immunocompromised patient treated with ribavirin.
Ambrosioni J; Mamin A; Hadengue A; Bernimoulin M; Samii K; Landelle C; Negro F; Kaiser L
Clin Microbiol Infect; 2014 Oct; 20(10):O718-20. PubMed ID: 24476456
[TBL] [Abstract][Full Text] [Related]
12. An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients.
Kamar N; Lhomme S; Abravanel F; Cointault O; Esposito L; Cardeau-Desangles I; Del Bello A; Dörr G; Lavayssière L; Nogier MB; Guitard J; Ribes D; Goin AL; Broué P; Metsu D; Sauné K; Rostaing L; Izopet J
Transplantation; 2015 Oct; 99(10):2124-31. PubMed ID: 26214817
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
van der Valk M; Zaaijer HL; Kater AP; Schinkel J
J Hepatol; 2017 Jan; 66(1):242-243. PubMed ID: 27702641
[No Abstract] [Full Text] [Related]
14. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
15. First Case Genotype 4 Hepatitis E Infection After a Liver Transplant.
Wu CH; Ho CM; Tsai JH; Sun HY; Hu RH; Lee PH
Exp Clin Transplant; 2017 Apr; 15(2):228-230. PubMed ID: 26221721
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis E virus.
Dalton HR; Kamar N
Curr Opin Infect Dis; 2016 Dec; 29(6):639-644. PubMed ID: 27607911
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
Friebus-Kardash J; Eisenberger U; Ackermann J; Kribben A; Witzke O; Wenzel J; Rohn H; Fiedler M
Transpl Infect Dis; 2019 Jun; 21(3):e13088. PubMed ID: 30929308
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin for chronic hepatitis E virus infection in transplant recipients.
Kamar N; Izopet J; Tripon S; Bismuth M; Hillaire S; Dumortier J; Radenne S; Coilly A; Garrigue V; D'Alteroche L; Buchler M; Couzi L; Lebray P; Dharancy S; Minello A; Hourmant M; Roque-Afonso AM; Abravanel F; Pol S; Rostaing L; Mallet V
N Engl J Med; 2014 Mar; 370(12):1111-20. PubMed ID: 24645943
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse.
Todt D; Meister TL; Steinmann E
Curr Opin Virol; 2018 Oct; 32():80-87. PubMed ID: 30384328
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin treatment of a patient with chronic hepatitis E. First case reported in Latin America.
Gruz F; Munné MS; González J; Lizarraga Villagran MA; Raffaele PP; Descalzi VI
Acta Gastroenterol Latinoam; 2016 Jun; 46(2):122-5. PubMed ID: 28704018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
